Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
藤黄健骨丸 (Tenghuang Bone-Strengthening Pills) is a traditional Chinese medicine (TCM) herbal formulation developed and manufactured by Shanxi Wanglong Pharmaceutical Group. It is a concentrated oral pill indicated for various orthopedic conditions, including hypertrophic spondylitis, cervical spondylosis, calcaneal spurs, proliferative arthritis, knee osteoarthritis, and Kashin-Beck disease. The formulation consists of several herbal ingredients: *Rehmannia glutinosa* (熟地黄), *Pyrola* (鹿衔草), *Drynaria* (骨碎补), *Cistanche* (肉苁蓉), *Epimedium* (淫羊藿), *Spatholobus* (鸡血藤), and *Radish seed* (莱菔子). According to TCM principles, it functions to tonify the kidney, invigorate blood circulation, and relieve pain. It is an approved prescription medicine in China and is included in the National Medical Insurance Category B.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 藤黄健骨丸.